Ronald D. Sugar Sells 2,000 Shares of Amgen, Inc. (AMGN) Stock

Amgen, Inc. (NASDAQ:AMGN) Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $190.00, for a total transaction of $380,000.00. Following the completion of the sale, the director now directly owns 14,988 shares in the company, valued at $2,847,720. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Amgen stock traded down $0.21 on Monday, hitting $185.79. The stock had a trading volume of 2,867,315 shares, compared to its average volume of 3,465,493. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19. The stock has a market capitalization of $118.52 billion, a price-to-earnings ratio of 12.90, a P/E/G ratio of 2.06 and a beta of 1.21.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The firm had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $5.88 billion. During the same quarter last year, the business earned $2.89 earnings per share. As a group, equities research analysts forecast that Amgen, Inc. will post 13.93 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $1.45 dividend. This is a boost from Amgen’s previous quarterly dividend of $1.32. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $5.80 annualized dividend and a dividend yield of 3.12%. Amgen’s dividend payout ratio (DPR) is currently 36.67%.

Several institutional investors have recently modified their holdings of AMGN. Wellington Shields & Co. LLC purchased a new stake in Amgen in the fourth quarter worth $820,000. Martingale Asset Management L P lifted its stake in Amgen by 0.3% in the fourth quarter. Martingale Asset Management L P now owns 31,780 shares of the medical research company’s stock worth $6,187,000 after acquiring an additional 100 shares during the period. State of Tennessee Treasury Department lifted its stake in Amgen by 6.8% in the fourth quarter. State of Tennessee Treasury Department now owns 257,461 shares of the medical research company’s stock worth $50,119,000 after acquiring an additional 16,379 shares during the period. Advisor Group Inc. lifted its stake in Amgen by 3.2% in the fourth quarter. Advisor Group Inc. now owns 86,134 shares of the medical research company’s stock worth $16,788,000 after acquiring an additional 2,691 shares during the period. Finally, Quantum Capital Management lifted its stake in Amgen by 8.8% in the fourth quarter. Quantum Capital Management now owns 5,126 shares of the medical research company’s stock worth $998,000 after acquiring an additional 415 shares during the period. Hedge funds and other institutional investors own 81.79% of the company’s stock.

A number of brokerages have commented on AMGN. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Amgen in a research report on Thursday, October 25th. Mizuho reiterated a “buy” rating and set a $206.00 price target on shares of Amgen in a research report on Friday, October 26th. Cantor Fitzgerald reiterated a “hold” rating and set a $223.00 price target on shares of Amgen in a research report on Wednesday, October 31st. Oppenheimer set a $224.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, October 30th. Finally, Royal Bank of Canada reduced their price target on shares of Amgen to $182.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 31st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $205.51.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2019/02/11/ronald-d-sugar-sells-2000-shares-of-amgen-inc-amgn-stock.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

See Also: What is the Bid-Ask Spread?

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply